Pfizer’s Xeljanz approved in Switzerland, first European country to approve the drug

July 15 2013 | By Márcio Barra

Pfizer just issued a press release where it reports that Switzerland’s SwissMedic has approved its rheumatoid arthritis treatment Xeljanz (tofacitinib citrate) for sale. This makes Switzerland the first European country to approve Xeljanz for adult patients with moderate-to-severe active RA who had an inadequate response or intolerance to the antirheumatic agent methotrexate.

View original post 273 more words

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s